Saurabh Johri

Saurabh Johri serves as the Chief Business Officer, bringing over two decades of expertise in strategy and commercialization within the healthcare and biopharmaceutical sectors. His career includes significant leadership roles across global and US markets at several top-tier biopharmaceutical companies. Notably, Johri worked at Bayer as the Vice President and Global Head of Oncology Strategy and Early Commercialization, where he was instrumental in shaping both short-term and long-term oncology strategies. His responsibilities at Bayer also included partnering with early R&D to align oncology pipeline development with strategic goals and collaborating with business development to support strategic deal flow and top-line objectives. Additionally, Johri led the US strategy and execution for LYNPARZA® (olaparib), a market-leading PARP inhibitor, across various tumor types. Prior to his tenure at Bayer, he held senior commercial roles at Merck and Teva Pharmaceuticals, focusing on new product planning and global strategy. Johri holds a degree in industrial engineering from Motilal Nehru National Institute of Technology and an MBA from Carnegie Mellon University.